DOCSLIB.ORG

Mucin-Selective Protease Stce Enables Molecular and Functional Analysis of Human Cancer-Associated Mucins

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Mucin-Selective Protease Stce Enables Molecular and Functional Analysis of Human Cancer-Associated Mucins The mucin-selective protease StcE enables molecular and functional analysis of human cancer-associated mucins Stacy A. Malakera,1, Kayvon Pedrama,1, Michael J. Ferracaneb, Barbara A. Bensingc, Venkatesh Krishnand, Christian Pette,f, Jin Yue, Elliot C. Woodsa, Jessica R. Kramerg, Ulrika Westerlinde,f, Oliver Dorigod, and Carolyn R. Bertozzia,h,2 aDepartment of Chemistry, Stanford University, Stanford, CA 94305; bDepartment of Chemistry, University of Redlands, Redlands, CA 92373; cDepartment of Medicine, San Francisco Veterans Affairs Medical Center and University of California, San Francisco, CA 94143; dStanford Women’s Cancer Center, Division of Gynecologic Oncology, Stanford University, Stanford, CA 94305; eLeibniz-Institut für Analytische Wissenschaften (ISAS), 44227 Dortmund, Germany; fDepartment of Chemistry, Umeå University, 901 87 Umeå, Sweden; gDepartment of Bioengineering, University of Utah, Salt Lake City, UT 84112; and hHoward Hughes Medical Institute, Stanford, CA 94305 Edited by Laura L. Kiessling, Massachusetts Institute of Technology, Cambridge, MA, and approved February 25, 2019 (received for review July 30, 2018) Mucin domains are densely O-glycosylated modular protein domains When strung together in “tandem repeats” mucin domains can that are found in a wide variety of cell surface and secreted proteins. form the large structures characteristic of mucin family proteins. Mucin-domain glycoproteins are known to be key players in a host Mucins can be hundreds to thousands of amino acids long of human diseases, especially cancer, wherein mucin expression and and >50% glycosylation by mass (11); MUC16, one of the largest glycosylation patterns are altered. Mucin biology has been difficult mucins, can exceed 22,000 residues and 85% glycosylation by mass to study at the molecular level, in part, because methods to manip- (12), with a persistence length of 1–5 μm (13). Due, in part, to their ulate and structurally characterize mucin domains are lacking. Here, presence at cellular peripheries, mucin family proteins are impor- we demonstrate that secreted protease of C1 esterase inhibitor tant mediators of cell–cell and cell–environment interactions, and (StcE), a bacterial protease from Escherichia coli, cleaves mucin do- have been under scrutiny for years due to their association with mains by recognizing a discrete peptide- and glycan-based motif. We exploited StcE’s unique properties to improve sequence cover- human cancer (14) (which must combat inhibitory cues from its surroundings at every stage of its progression). Indeed, the age, glycosite mapping, and glycoform analysis of recombinant hu- BIOCHEMISTRY man mucins by mass spectrometry. We also found that StcE digests membrane-associated mucin MUC1 is aberrantly expressed in cancer-associated mucins from cultured cells and from ascites ∼60% of all cancers diagnosed each year in the United States fluid derived from patients with ovarian cancer. Finally, using (15), rendering MUC1 one of the most prominently dysregulated StcE, we discovered that sialic acid-binding Ig-type lectin-7 genes in cancer. Functionally, recent work has shown that the (Siglec-7), a glycoimmune checkpoint receptor, selectively binds MUC1 ectodomain alone can drive tumor growth by enhancing sialomucins as biological ligands, whereas the related receptor cancer cell survival and promoting proliferation through biophysical Siglec-9 does not. Mucin-selective proteolysis, as exemplified by pathways (16). The large mucin MUC16 (also called CA-125) is StcE, is therefore a powerful tool for the study of mucin domain highly expressed in ovarian cancer and is used as a clinical bio- structure and function. marker for treatment efficacy and surveillance (17). Observations such as these have motivated numerous efforts toward mucin-based O-glycosylation | mucin | protease | glycoproteomics | Siglec Significance ucin domains are modular protein domains characterized Mby a high frequency of Ser and Thr residues that are O- Mucin-domain glycoproteins are found in nearly every tissue of glycosylated with α-N-acetylgalactosamine (α-GalNAc). The α the human body, and are important in biological processes initial glycosylation with -GalNAc and elaboration to larger ranging from embryogenesis to cancer. Because there are few glycan structures occur through complex, interdependent meta- tools to study mucin domains, their biological functions at the bolic pathways to which hundreds of genes can contribute. The molecular scale remain unclear. Here, we help address a hurdle resulting glycoprotein population is highly heterogeneous and to the study of mucin-domain glycoproteins by characterizing a dynamic, and cannot be predicted based on genomic information bacterial protease with selectivity for mucins. This mucinase alone (1). Dense spacing of these heterogeneous O-glycans “ selectively removes native mucins from cell surfaces and cuts forces the underlying polypeptide to adopt a unique mucin them into fragments amenable to analysis. fold,” which is rigid and extended (2) (Fig. 1A, Left). The mucin fold is found in a wide variety of cell surface and secreted pro- Author contributions: S.A.M., K.P., and C.R.B. designed research; S.A.M., K.P., M.J.F., and teins of various families, analogous to the common Ig fold (3). B.A.B. performed research; V.K., C.P., J.Y., J.R.K., U.W., and O.D. contributed new re- Mucin-domain glycoproteins contribute to many biological agents/analytic tools; S.A.M., K.P., M.J.F., B.A.B., E.C.W., and C.R.B. analyzed data; and processes. For example, they are involved in embryogenesis (4), S.A.M., K.P., and C.R.B. wrote the paper. barrier formation (5), host–pathogen interactions (6), and im- Conflict of interest statement: A patent application relating to the use of enzymes to mune signaling (7). Due to their stiff, elongated, and highly hy- digest mucin-domain glycoproteins has been filed by Stanford University (docket no. STAN-1510PRV). C.R.B. is a cofounder and Scientific Advisory Board member of Palleon drated structures, mucin domains are also important modulators Pharmaceuticals, Enable Bioscience, Redwood Biosciences (a subsidiary of Catalent), and of cell- and protein-level biophysics (8). For example, CD45R0 is InterVenn Biosciences, and a member of the Board of Directors of Eli Lilly & Company. a conserved splice variant of the T cell marker CD45, in which O.D. has participated in advisory boards for Tesaro, Merck, and Geneos. O.D. is a speaker three exons encoding mucin domains are missing. The loss of the for Tesaro and AstraZeneca. mucin domains promotes dimerization, abrogating intracellular This article is a PNAS Direct Submission. tyrosine phosphatase activity needed for T cell activation, and Published under the PNAS license. thereby aiding activated T cells in regulated cessation of their 1S.A.M. and K.P. contributed equally to this work. response (9). Mucin domains also serve as receptor ligands. For 2To whom correspondence should be addressed. Email: [email protected]. example, the binding of P-selectin to its ligand, P-selectin gly- This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10. coprotein ligand-1 (PSGL-1), a mucin-domain glycoprotein, is an 1073/pnas.1813020116/-/DCSupplemental. essential component of leukocyte rolling and adhesion (10). www.pnas.org/cgi/doi/10.1073/pnas.1813020116 PNAS Latest Articles | 1of10 Downloaded by guest on September 30, 2021 A (OSGEP) is a commercial enzyme historically marketed as having mucin-degrading activity. Unfortunately, OSGEP’sapparentac- tivity has not been tied to a gene sequence that is amenable to recombinant expression, prompting the current view that OSGEP may act as a mixture of several unknown enzymes (29). The ubiquitous and highly conserved nature of mucin struc- tures implies an ecological need for enzymes with mucin-specific proteolytic activity. Indeed, recent evidence has pointed to the existence of families of mucin-targeting proteases comprising Mucinase cell cell hundreds of enzymes largely found in organisms living in mucin- rich host environments (30–32).Onesuchenzyme,secretedprotease B C Degly. mix of C1 esterase inhibitor (StcE), is a zinc metalloprotease of hu- man pathogenic enterohemorrhagic Escherichia coli (EHEC). rhMUC16PODXLCD43 PSGL1Syncam1CD45 BSA Fetuin Discovered by Welch and coworkers (33) and crystallized by StcE – +–+–+–+–+–+–+–+ – StcEE447DTrypsin– StcEE447DTrypsin Strynadka and coworkers (34), StcE promotes EHEC patho- 198 180 98 82 genesis in humans by cleaving the protective mucus layers of the 62 gut (35, 36). It is reported to cleave densely O-glycosylated 49 42 proteins, but not N-glycosylated or sparsely O-glycosylated sub- 38 strates (31). Given these reported pathogenic properties, we 28 17 18 speculated that StcE could be transformed into a research tool to 14 efficiently and selectively cleave human mucins. Mucin-specific proteolysis would be a valuable addition to the biochemist’s 6 toolbox, enabling mucin-domain glycoproteins to be selectively Fig. 1. StcE is a protease that selectively cleaves mucins. (A) A mucinase liberated from biological samples and cut into fragments ame- would enable mucin-domain glycoproteins to be selectively removed from nable to analysis (Fig. 1A, Right). biological samples and cut into fragments, facilitating their analysis. Cellular Here, we report that StcE has a distinct peptide- and glycan- and tissue experiments are depicted in Figs. 5 and 6. (B) Recombinant gly- based cleavage motif that enables
Load more

Recommended publications
  • Platelet Membrane Glycoproteins: a Historical Review*
    577 Platelet Membrane Glycoproteins: A Historical Review* Alan T. Nurden, PhD1 1 L’Institut de Rhythmologie et Modélisation Cardiaque (LIRYC), Address for correspondence Alan T. Nurden, PhD, L’Institut de Plateforme Technologique et d’Innovation Biomédicale (PTIB), Rhythmologie et Modélisation Cardiaque, Plateforme Technologique Hôpital Xavier Arnozan, Pessac, France et d’Innovation Biomédicale, Hôpital Xavier Arnozan, Avenue du Haut- Lévèque, 33600 Pessac, France (e-mail: [email protected]). Semin Thromb Hemost 2014;40:577–584. Abstract The search for the components of the platelet surface that mediate platelet adhesion and platelet aggregation began for earnest in the late 1960s when electron microscopy demonstrated the presence of a carbohydrate-rich, negatively charged outer coat that was called the “glycocalyx.” Progressively, electrophoretic procedures were developed that identified the major membrane glycoproteins (GP) that constitute this layer. Studies on inherited disorders of platelets then permitted the designation of the major effectors of platelet function. This began with the discovery in Paris that platelets of patients with Glanzmann thrombasthenia, an inherited disorder of platelet aggregation, Keywords lacked two major GP. Subsequent studies established the role for the GPIIb-IIIa complex ► platelet (now known as integrin αIIbβ3)inbindingfibrinogen and other adhesive proteins on ► inherited disorder activated platelets and the formation of the protein bridges that join platelets together ► membrane in the platelet aggregate. This was quickly followed by the observation that platelets of glycoproteins patients with the Bernard–Soulier syndrome, with macrothrombocytopenia and a ► Glanzmann distinct disorder of platelet adhesion, lacked the carbohydrate-rich, negatively charged, thrombasthenia GPIb. It was shown that GPIb, through its interaction with von Willebrand factor, ► Bernard–Soulier mediated platelet attachment to injured sites in the vessel wall.
    [Show full text]
  • Early Acute Microvascular Kidney Transplant Rejection in The
    CLINICAL RESEARCH www.jasn.org Early Acute Microvascular Kidney Transplant Rejection in the Absence of Anti-HLA Antibodies Is Associated with Preformed IgG Antibodies against Diverse Glomerular Endothelial Cell Antigens Marianne Delville,1,2,3 Baptiste Lamarthée,4 Sylvain Pagie,5,6 Sarah B. See ,7 Marion Rabant,3,8 Carole Burger,3 Philippe Gatault ,9,10 Magali Giral,11 Olivier Thaunat,12,13,14 Nadia Arzouk,15 Alexandre Hertig,16,17 Marc Hazzan,18,19,20 Marie Matignon,21,22,23 Christophe Mariat,24,25 Sophie Caillard,26,27 Nassim Kamar,28,29 Johnny Sayegh,30,31 Pierre-François Westeel,32 Cyril Garrouste,33 Marc Ladrière,34 Vincent Vuiblet,35 Joseph Rivalan,36 Pierre Merville,37,38,39 Dominique Bertrand,40 Alain Le Moine,41,42 Jean Paul Duong Van Huyen,3,8 Anne Cesbron,43 Nicolas Cagnard,3,44 Olivier Alibeu,3,45 Simon C. Satchell,46 Christophe Legendre,3,4,47 Emmanuel Zorn,7 Jean-Luc Taupin,48,49,50 Béatrice Charreau,5,6 and Dany Anglicheau 3,4,47 Due to the number of contributing authors, the affiliations are listed at the end of this article. ABSTRACT Background Although anti-HLA antibodies (Abs) cause most antibody-mediated rejections of renal allo- grafts, non-anti–HLA Abs have also been postulated to contribute. A better understanding of such Abs in rejection is needed. Methods We conducted a nationwide study to identify kidney transplant recipients without anti-HLA donor-specific Abs who experienced acute graft dysfunction within 3 months after transplantation and showed evidence of microvascular injury, called acute microvascular rejection (AMVR).
    [Show full text]
  • Soluble Factor in Normal Tissues That Stimulates High-Molecular-Weight Sialoglycoprotein Production by Human Colon Carcinoma Cells1
    (CANCER RESEARCH 50, 3331-3338. June I, I990| Soluble Factor in Normal Tissues That Stimulates High-Molecular-Weight Sialoglycoprotein Production by Human Colon Carcinoma Cells1 Tatsuro Irimura,2 Andrew M. Mclsaac, Debora A. Carlson, Masato Vagita, Elizabeth A. Grimm, David G. Menter, David M. Ota, and Karen R. Cleary Departments of Tumor Biology IT. I., A. M., D. A. C., M. Y., E. A. G., D. G. M.], General Surgery /E. A. G., D. M. O.J, and Pathology [K. R. C.J, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030 ABSTRACT linked carbohydrate chains. Secreted mucins are believed to function as protective molecules and as lubricants on tissue The stimulation of high molecular »eight Sialoglycoprotein synthesis surfaces. Despite previous attempts by several laboratories to by a soluble factor derived from normal colon tissues was studied in vitro with human colon carcinoma cell lines, HT-29 P and a metastatic variant classify and characterize colorectal mucins, it remained unclear HT-29 LMM. The synthesis of all three high-molecular-weight sialo- whether a specific biological function is associated with unique glycoproteins (approximate M, 900,000, 740,000, and 450,000) by HT- carbohydrate structures in these mucins (10,13-22). Our recent 29 P cells or HT-29 LMM cells growing in vitro was enhanced by studies utilizing pathological specimens of colorectal carcinoma supplementing the culture medium with a conditioned medium of fresh suggested that at least four mucin-like glycoproteins with dif human colon organ culture. Changes were detected by polyacrylamide ferent carbohydrate chains were independently regulated and gel electrophoresis of lysates from [3H)glucosamine-labeled cells on 3% either directly or inversely correlated with the metastatic poten gels followed by fluorography, or by electrophoresis of lysates from tial of these malignant tumors (23-27).3 Thus, these changes unlabeled cells followed by incubation with '"I-labeled wheat germ were apparently associated with the progression of colon car agglutinin and autoradiography.
    [Show full text]
  • Antimicrobial Glycoconjugate Vaccines: an Overview of Classic and Modern Approaches Cite This: Chem
    Chem Soc Rev View Article Online TUTORIAL REVIEW View Journal | View Issue Antimicrobial glycoconjugate vaccines: an overview of classic and modern approaches Cite this: Chem. Soc. Rev., 2018, 47, 9015 for protein modification Francesco Berti * and Roberto Adamo * Glycoconjugate vaccines obtained by chemical linkage of a carbohydrate antigen to a protein are part of routine vaccinations in many countries. Licensed antimicrobial glycan–protein conjugate vaccines are obtained by random conjugation of native or sized polysaccharides to lysine, aspartic or glutamic amino acid residues that are generally abundantly exposed on the protein surface. In the last few years, the structural approaches for the definition of the polysaccharide portion (epitope) responsible for the immunological activity has shown potential to aid a deeper understanding of the mode of action of glycoconjugates and to lead to the rational design of more efficacious and safer vaccines. The combination of technologies to obtain more defined carbohydrate antigens of higher purity and novel approaches for Creative Commons Attribution-NonCommercial 3.0 Unported Licence. Received 12th June 2018 protein modification has a fundamental role. In particular, methods for site selective glycoconjugation like DOI: 10.1039/c8cs00495a chemical or enzymatic modification of specific amino acid residues, incorporation of unnatural amino acids and glycoengineering, are rapidly evolving. Here we discuss the state of the art of protein engineering with rsc.li/chem-soc-rev carbohydrates to obtain glycococonjugates vaccines and future perspectives. Key learning points (a) The covalent linkage with proteins is fundamental to transform carbohydrates, which are per se T-cell independent antigens, in immunogens capable of This article is licensed under a evoking a long-lasting T-cell memory response.
    [Show full text]
  • Sialylated Keratan Sulfate Chains Are Ligands for Siglec-8 in Human Airways
    Sialylated Keratan Sulfate Chains are Ligands for Siglec-8 in Human Airways by Ryan Porell A dissertation submitted to Johns Hopkins University in conformity with the requirements for the degree of Doctor of Philosophy Baltimore, Maryland September 2018 © 2018 Ryan Porell All Rights Reserved ABSTRACT Airway inflammatory diseases are characterized by infiltration of immune cells, which are tightly regulated to limit inflammatory damage. Most members of the Siglec family of sialoglycan binding proteins are expressed on the surfaces of immune cells and are immune inhibitory when they bind their sialoglycan ligands. When Siglec-8 on activated eosinophils and mast cells binds to its sialoglycan ligands, apoptosis or inhibition of mediator release is induced. We identified human airway Siglec-8 ligands as sialylated and 6’-sulfated keratan sulfate (KS) chains carried on large proteoglycans. Siglec-8- binding proteoglycans from human airways increase eosinophil apoptosis in vitro. Given the structural complexity of intact proteoglycans, target KS chains were isolated from airway tissue and lavage. Biological samples were extensively proteolyzed, the remaining sulfated glycan chains captured and resolved by anion exchange chromatography, methanol-precipitated then chondroitin and heparan sulfates enzymatically hydrolyzed. The resulting preparation consisted of KS chains attached to a single amino acid or a short peptide. Purified KS chains were hydrolyzed with either hydrochloric acid or trifluoroacetic acid to release acidic and neutral sugars, respectively, followed by DIONEX carbohydrate analysis. To isolate Siglec-8-binding KS chains, purified KS chains from biological samples were biotinylated at the amino acid, resolved by affinity and/or size- exclusion chromatography, the resulting fractions immobilized on streptavidin microwell plates, and probed for binding of Siglec-8-Fc.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7,998,740 B2 Sackstein (45) Date of Patent: Aug
    US007998.740B2 (12) United States Patent (10) Patent No.: US 7,998,740 B2 Sackstein (45) Date of Patent: Aug. 16, 2011 (54) CYTOKINE INDUCTION OF SELECTIN Butcher, E. C., "Leukocyte-endothelial cell recognition: three (or LGANDS ON CELLS more) steps to specificity and diversity”. Cell, 67: 1033-6 (1991). Cowlandet al., “Isolation of neutrophil precursors from bone marrow (76) Inventor: Robert Sackstein, Sudbury, MA (US) for biochemical and transcriptional analysis”. J. Immunol. Meth. 232:191-200 (1999). (*) Notice: Subject to any disclaimer, the term of this Dereure et al., “Neutrophil-dependent cutaneous side-effects of patent is extended or adjusted under 35 leucocyte colony-stimulating factors: manifestations of a neutrophil U.S.C. 154(b) by 325 days. recovery syndrome'. Brit. J. Dermatol., 150: 1228-30 (2004). Dimitroff et al., “CD44 is a major E-selectin ligand on human (21) Appl. No.: 11/779,650 hematopoietic progenitor cells'. J. Cell. Biol. 153:1277-86 (2001). Dimitroffet al., “A distinct glycoform of CD44 is an L-selectin ligand (22) Filed: Jul.18, 2007 on human hematopoietic cells'. Proc. Natl. Acad. Sci. USA, (65) Prior Publication Data 97:13841-6 (2000). Dimitroffet al., “Differential L-selectin binding activities of human US 2009/00531.98 A1 Feb. 26, 2009 hematopoietic cell L-selectin ligands, Hcell and PSGL-1”. J. Biol. Chem., 276:47623-31 (2001). Related U.S. Application Data Elfenbein et al., “Primed marrow for autologous and allogeneic trans (60) Provisional application No. 60/831,525, filed on Jul. plantation: a review comparing primed marrow to mobilized blood 18, 2006. and steady-state marrow”.
    [Show full text]
  • Antiluteogenic Effects of Serial Prostaglandin F2α Administration in Mares
    ANTILUTEOGENIC EFFECTS OF SERIAL PROSTAGLANDIN F2α ADMINISTRATION IN MARES Thesis Presented in partial fulfillment of the requirements for the Master of Science in the Graduate School of The Ohio State University Elizabeth Ann Coffman Graduate ProGram in Comparative and Veterinary Medicine The Ohio State University 2013 Thesis committee: Carlos R.F. Pinto PhD, MV, DACT; Dissertation Advisor Marco A. Coutinho da Silva PhD, MV, DACT; Academic Advisor Christopher Premanandan PhD, DVM, DACVP Copyright by Elizabeth Ann Coffman 2013 Abstract For breedinG manaGement and estrus synchronization, prostaGlandin F2α (PGF) is one of the most commonly utilized hormones to pharmacologically manipulate the equine estrous cycle. There is a general supposition a sinGle dose of PGF does not consistently induce luteolysis in the equine corpus luteum (CL) until at least five to six days after ovulation. This leads to the erroneous assumption that the early CL (before day five after ovulation) is refractory to the luteolytic effects of PGF. An experiment was desiGned to test the hypotheses that serial administration of PGF in early diestrus would induce a return to estrus similar to mares treated with a sinGle injection in mid diestrus, and fertility of the induced estrus for the two treatment groups would not differ. The specific objectives of the study were to evaluate the effects of early diestrus treatment by: 1) assessing the luteal function as reflected by hormone profile for concentration of plasma progesterone; 2) determininG the duration of interovulatory and treatment to ovulation intervals; 3) comparing of the number of pregnant mares at 14 days post- ovulation. The study consisted of a balanced crossover desiGn in which reproductively normal Quarter horse mares (n=10) were exposed to two treatments ii on consecutive reproductive cycles.
    [Show full text]
  • Incidental Finding of Raised CA125
    Case Report iMedPub Journals Critical Care Obstetrics and Gynecology 2019 http://www.imedpub.com/ Vol.5 No.1:3 ISSN 2471-9803 DOI: 10.21767/2471-9803.1000170 Incidental Finding of Raised CA125: a Cause for Concern? Farshad Tahmasebi1*, Rahul Nath1, Nava Sokolovsky1, Johannah Scaffidi1, Jane Boley1, Gautam Mehra1 and Ahmad Sayanseh1,2 1Department of Gynaecological Oncology, St Thomas’ Hospital, London, UK 2School of Life Course Sciences, King’s College London, Guy’s, Kings College and St. Thomas’ Hospital, London, UK, School of Medical Education, King’s College, London, UK *Corresponding author: Farshad Tahmasebi, Department of Gynaecological Oncology, St Thomas’ Hospital, London, UK, E-mail: [email protected] Received date: October 30, 2018; Accepted date: November 15, 2018; Published date: November 21, 2018 Copyright: © 2018 Tahmasebi F, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Citation: Tahmasebi F, Nath R, Sokolovsky N, Scaffidi J, Boley J, et al. (2018) Incidental Finding of Raised CA125: a Cause for Concern? Crit Care Obst Gyne Vol.5 No.1:3. Although much research has been done to understand the molecular structure of CA 125, its functions remain a source of Abstract much speculation. It is expressed in tissues derived from embryonic coelomic epithelium such as endometrium, Mullerian Cancer antigen 125 (also known as carbohydrate antigen epithelium, peritoneum, pleura and pericardium [4]. Within 125 or CA 125) is an antigen first identified by Bast et al.
    [Show full text]
  • TACI:Fc Scavenging B Cell Activating Factor (BAFF) Alleviates Ovalbumin-Induced Bronchial Asthma in Mice
    EXPERIMENTAL and MOLECULAR MEDICINE, Vol. 39, No. 3, 343-352, June 2007 TACI:Fc scavenging B cell activating factor (BAFF) alleviates ovalbumin-induced bronchial asthma in mice 1,2,3 2 Eun-Yi Moon and Sook-Kyung Ryu the percentage of non-lymphoid cells and no changes were detected in lymphoid cell population. 1 Department of Bioscience and Biotechnology Hypodiploid cell formation in BALF was decreased Sejong University by OVA-challenge but it was recovered by TACI:Fc Seoul 143-747, Korea treatment. Collectively, data suggest that asthmatic 2 Laboratory of Human Genomics symptom could be alleviated by scavenging BAFF Korea Research Institute of Bioscience and Biotechnology (KRIBB) and then BAFF could be a novel target for the Daejeon 305-806, Korea develpoment of anti-asthmatic agents. 3 Corresponding author: Tel, 82-2-3408-3768; Fax, 82-2-466-8768; E-mail, [email protected] Keywords: asthma; B-cell activating factor; ovalbu- and [email protected] min; transmembrane activator and CAML interactor protein Accepted 28 March 2007 Introduction Abbreviations: BAFF, B cell activating factor belonging to TNF- family; BALF, bronchoalveolar lavage fluid; OVA, ovalbumin; PAS, Mature B cell generation and maintenance are regu- periodic acid-Schiff; Prx, peroxiredoxin; TACI, transmembrane lated by B-cell activating factor (BAFF). BAFF is pro- activator and calcium modulator and cyclophilin ligand interactor duced by macrophages or dendritic cells upon stim- ulation with LPS or IFN- . BAFF belongs to the TNF family. Its biological role is mediated by the specific Abstract receptors, B-cell maturation antigen (BCMA), trans- membrane activator and calcium modulator and cy- Asthma was induced by the sensitization and chal- clophilin ligand interactor (TACI) and BAFF receptor, lenge with ovalbumin (OVA) in mice.
    [Show full text]
  • Mucins: the Old, the New and the Promising Factors in Hepatobiliary Carcinogenesis
    International Journal of Molecular Sciences Review Mucins: the Old, the New and the Promising Factors in Hepatobiliary Carcinogenesis Aldona Kasprzak 1,* and Agnieszka Adamek 2 1 Department of Histology and Embryology, Poznan University of Medical Sciences, Swiecicki Street 6, 60-781 Pozna´n,Poland 2 Department of Infectious Diseases, Hepatology and Acquired Immunodeficiencies, University of Medical Sciences, Szwajcarska Street 3, 61-285 Pozna´n,Poland; [email protected] * Correspondence: [email protected]; Tel.: +48-61-8546441; Fax: +48-61-8546440 Received: 25 February 2019; Accepted: 10 March 2019; Published: 14 March 2019 Abstract: Mucins are large O-glycoproteins with high carbohydrate content and marked diversity in both the apoprotein and the oligosaccharide moieties. All three mucin types, trans-membrane (e.g., MUC1, MUC4, MUC16), secreted (gel-forming) (e.g., MUC2, MUC5AC, MUC6) and soluble (non-gel-forming) (e.g., MUC7, MUC8, MUC9, MUC20), are critical in maintaining cellular functions, particularly those of epithelial surfaces. Their aberrant expression and/or altered subcellular localization is a factor of tumour growth and apoptosis induced by oxidative stress and several anti-cancer agents. Abnormal expression of mucins was observed in human carcinomas that arise in various gastrointestinal organs. It was widely believed that hepatocellular carcinoma (HCC) does not produce mucins, whereas cholangiocarcinoma (CC) or combined HCC-CC may produce these glycoproteins. However, a growing number of reports shows that mucins can be produced by HCC cells that do not exhibit or are yet to undergo, morphological differentiation to biliary phenotypes. Evaluation of mucin expression levels in precursors and early lesions of CC, as well as other types of primary liver cancer (PLC), conducted in in vitro and in vivo models, allowed to discover the mechanisms of their action, as well as their participation in the most important signalling pathways of liver cystogenesis and carcinogenesis.
    [Show full text]
  • MUC16 (CA125): Tumor Biomarker to Cancer Therapy, a Work in Progress
    Felder et al. Molecular Cancer 2014, 13:129 http://www.molecular-cancer.com/content/13/1/129 REVIEW Open Access MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress Mildred Felder1†, Arvinder Kapur1†, Jesus Gonzalez-Bosquet2, Sachi Horibata1, Joseph Heintz3, Ralph Albrecht3, Lucas Fass1, Justanjyot Kaur1, Kevin Hu4, Hadi Shojaei1, Rebecca J Whelan4* and Manish S Patankar1* Abstract Over three decades have passed since the first report on the expression of CA125 by ovarian tumors. Since that time our understanding of ovarian cancer biology has changed significantly to the point that these tumors are now classified based on molecular phenotype and not purely on histological attributes. However, CA125 continues to be, with the recent exception of HE4, the only clinically reliable diagnostic marker for ovarian cancer. Many large-scale clinical trials have been conducted or are underway to determine potential use of serum CA125 levels as a screening modality or to distinguish between benign and malignant pelvic masses. CA125 is a peptide epitope of a3–5 million Da mucin, MUC16. Here we provide an in-depth review of the literature to highlight the importance of CA125 as a prognostic and diagnostic marker for ovarian cancer. We focus on the increasing body of literature describing the biological role of MUC16 in the progression and metastasis of ovarian tumors. Finally, we consider previous and on-going efforts to develop therapeutic approaches to eradicate ovarian tumors by targeting MUC16. Even though CA125 is a crucial marker for ovarian cancer, the exact structural definition of this antigen continues to be elusive. The importance of MUC16/CA125 in the diagnosis, progression and therapy of ovarian cancer warrants the need for in-depth research on the biochemistry and biology of this mucin.
    [Show full text]
  • Adherence of Mycoplasma Gallisepticum to Human Erythrocytes M
    INFECTION AND IMMUNITY, Aug. 1978, p. 365-372 Vol. 21, No. 2 0019-9567/78/0021-0365$02.00/0 Copyright i 1978 American Society for Microbiology Printed in U.S.A. Adherence of Mycoplasma gallisepticum to Human Erythrocytes M. BANAI,1 I. KAHANE,' S. RAZINl* AND W. BREDT2 Biomembrane Research Laboratory, Department of Clinical Microbiology, The Hebrew University- Hadassah Medical School, Jerusalem, Israel,' and Institute for General Hygiene and Bacteriology, Center for Hygiene, Albert-Ludwigs- Universitat, D- 7800 Freiburg, West Germany Received for publication 7 February 1978 Pathogenic mycoplasmas adhere to and colonize the epithelial lining of the respiratory and genital tracts ofinfected animals. An experimental system suitable for the quantitative study of mycoplasma adherence has been developed by us. The system consists of human erythrocytes (RBC) and the avian pathogen Mycoplasma gallisepticum, in which membrane lipids were labeled. The amount of mycoplasma cells attached to the RBC, which was determined according to radioactivity measurements, decreased on increasing the pH or ionic strength of the attachment mixture. Attachment followed first-order kinetics and depended on temperature. The mycoplasma cell population remaining in the supernatant fluid after exposure to RBC showed a much poorer ability to attach to RBC during a second attachment test, indicating an unequal distribution of binding sites among cells within a given population. The gradual removal of sialic acid residues from the RBC by neuraminidase was accompanied by a decrease in mycoplasma attachment. Isolated glycophorin, the RBC membrane glycoprotein carrying almost all the sialic acid moieties ofthe RBC, inhibited M. gallisepticum attachment, whereas asialoglycophorin and sialic acid itself were very poor inhibitors of attachment.
    [Show full text]